C4 Therapeutics Inc Total Liabilities
C4 Therapeutics Inc total liabilities. Based on the latest financial reports, C4 Therapeutics Inc (CCCC) has total liabilities worth $112.14 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check C4 Therapeutics Inc (CCCC) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of C4 Therapeutics Inc (2018–2025)
Total liabilities of C4 Therapeutics Inc from 2018 to 2025. This chart illustrates how C4 Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore CCCC strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
C4 Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of C4 Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AdvanSix Inc
NYSE:ASIX
|
USA | $876.10 Million |
|
Beijing Emerging Eastern Aviation Equipment Co Ltd Class A
SHE:002933
|
China | CN¥708.72 Million |
|
Traffic Control Technology Co Ltd
SHG:688015
|
China | CN¥3.38 Billion |
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
China | CN¥1.45 Billion |
|
InPlay Oil Corp
TO:IPO
|
Canada | CA$795.00 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$12.96 Million |
|
Beijing Jingyeda Technology Co Ltd
SHE:003005
|
China | CN¥293.89 Million |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
China | CN¥228.04 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down C4 Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see C4 Therapeutics Inc assets under control.
Liquidity & Leverage Metrics
C4 Therapeutics Inc Total Liabilities Ratios Explained
C4 Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how C4 Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for C4 Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of C4 Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $102.49 Million | -23.30% |
| 2024-12-31 | $133.62 Million | +2.52% |
| 2023-12-31 | $130.34 Million | -7.96% |
| 2022-12-31 | $141.61 Million | +20.87% |
| 2021-12-31 | $117.16 Million | -1.83% |
| 2020-12-31 | $119.35 Million | -48.16% |
| 2019-12-31 | $230.22 Million | +1.76% |
| 2018-12-31 | $226.24 Million | -- |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more